Exciting 2 see ultrasensitive MRD as dynamic clinical tool. In GYN cancers I’ve seen hesitation around ctDNA testing, centered on “what will we do with that information?” How do we close that gap so evidence generation & clinical adoption move together across tumor types? #AACR26